Patents
US 12577540 B2: Suspension mode seed train development for adherent cells
- Granted
- 2026-03-17
- Filed
- 2021-12-09 application 18255221
- Type
- Utility · 32 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
The disclosure is directed to a method for seed train expansion of adherent cells comprising culturing cells with a serum-supplemented growth medium in a N-2 vessel; removing the cells from the serum-supplemented medium; inoculating the cells from step into a serum-free growth medium in a N-1 vessel; culturing the cells in the N-1 vessel under suspension conditions; and inoculating a growth medium in a bioreactor with the suspension-cultured cells. In some aspects, the adherent cells are not suspension-adapted. In some aspects, the adherent cells are suspension-adapted. In some aspects, the adherent cells produced by the seed train expansion method are used to produce viral vectors. In some aspects, the viral vectors are AAV vectors.
Source: PTBLXML, file of 2026-03-17 (ipgb20260317.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| Sarepta Therapeutics, Inc. 126 patents | US company or organization | Cambridge, MA | Sarepta Therapeutics, Inc. Form D issuer EXACT high confidence: identical full name and state SAREPTA THERAPEUTICS, INC. SEC filer EXACT medium confidence: identical full name, one of each nationally | PTBLXML, file of 2026-03-17 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Maroof Alam | Cambridge, MA | PTBLXML, file of 2026-03-17 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| C12N | Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media | C12N7/00 | PTBLXML, file of 2026-03-17 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2025-05-07 | Security interest Security interest Security interest | SAREPTA THERAPEUTICS, INC. signed 2025-02-13 | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT CHICAGO, IL | 71218/445 | PASDL, file of 2026-10-15 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.